RE:RE:Volume 131,400 in Canada Companies working on drug or nutraceutical development can never be sure that their formulation will become a commercial success. Investors must consider that possibility when deciding on whether or not to invest in a company with a pipeline that may or may not become a profitable venture. If one of Ceapro’s potential formulation is successfully marketed, then the share price will react positively. Because of its strong balance sheet and very profitable operating business, if Ceapro’s pipeline turns out to be a flop, the share price will remain stagnant.
Ceapro offers little downside risk.
| | Trailing |
| | Twelve-months |
| Revenue | $19,079,000 |
| | |
| Net income | $6,627,000 |
| | |
| Cash generated from operations | $6,317,000 |
| | |
| Investing activities | ($523,000) |
| Financing activities | ($295,000) |
| | |
| Share price (2022-12-29) | $0.60 |
| | |
| Number of outstanding shares | 78,218,177 |
| Number of stock options | 2,347,999 |
| Total number of shares | 80,566,176 |
| Market cap | $48,339,706 |
| Cash | $12,910,069 |
| Cash from options | $1,129,480 |
| Debt | $0 |
| Enterprise value | $34,300,157 |
| TTM Operating Cash flows (OCF) | $6,317,000 |
| TTM cash flow yield / Enterprise Value | 16.1% |
| Enterprise Value / OCF | 6.2 |